Cornerstone Capital Management’s Alexion Pharmaceuticals ALXN Stock Holding History

Cornerstone Capital Management’s Portfolio ALXN Stock Details ALXN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q3	$18.8M	Sell	153,765 -316,583	-67%	-$40.8M	2.97%	11
2016 Q2	$54.9M	Buy	470,348 +1,089	+0.2%	+$155K	2.9%	14
2016 Q1	$65.3M	Buy	469,259 +114,870	+32%	+$16.9M	2.85%	14
2015 Q4	$67.6M	Sell	354,389 -90,150	-20%	-$15.7M	2.76%	13
2015 Q3	$69.5M	Sell	444,539 -62,949	-12%	-$11.5M	2.95%	10
2015 Q2	$91.7M	Buy	507,488 +166,835	+49%	+$28.8M	3.01%	9
2015 Q1	$59M	Buy	340,653 +109,046	+47%	+$19.7M	1.95%	28
2014 Q4	$42.9M	Sell	231,607 -49,095	-17%	-$9.1M	1.39%	35
2014 Q3	$46.5M	Sell	280,702 -15,257	-5%	-$2.51M	1.52%	29
2014 Q2	$46.2M	Buy	295,959 +199,937	+208%	+$31.6M	1.48%	32
2014 Q1	$14.6M	Buy	+96,022	New	+$15.3M	0.47%	46

Other funds holding ALXN

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

Cornerstone Capital Management's ALXN Position: Q3 2016 in Review

Cornerstone Capital Management reduced its Alexion Pharmaceuticals (ALXN) stake by 67% in Q3 2016, selling an estimated $40.8M and leaving 153,765 shares worth $18.8M. The position accounts for 2.97% of the portfolio, ranked #11.

Cornerstone Capital Management first reported a position in ALXN in Q1 2014 and has held it in 11 quarters since. The position peaked at $91.7M in Q2 2015. 517 funds tracked by Wall St. Rank hold ALXN as of Q3 2016.

Cornerstone Capital Management held 153,765 shares of Alexion Pharmaceuticals worth $18.8M as of Q3 2016.
Cornerstone Capital Management sold 316,583 Alexion Pharmaceuticals shares in Q3 2016, an estimated $40.8M.
Alexion Pharmaceuticals made up 2.97% of Cornerstone Capital Management's portfolio in Q3 2016, its #11 holding.
Cornerstone Capital Management first reported a position in Alexion Pharmaceuticals in Q1 2014 and has held it in 11 quarters since.
Cornerstone Capital Management's Alexion Pharmaceuticals position peaked at $91.7M in Q2 2015.
517 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2016.

Based on Cornerstone Capital Management's 13F filing for Q3 2016, filed 3 Nov 2016.